Tinnitus — Current Developments: Overview and Summary of Current State of Knowledge in 2024

[Frédéric]

[Tinnitus-current developments : Overview and summary of current state of knowledge in 2024] - PubMed

Chronic tinnitus is a common symptom of the auditory system. Its pathophysiology remains incompletely understood, primarily due to its multifactorial etiology, which resembles that of other chronic conditions. As a result, effective clinical management requires interdisciplinary diagnostics and...

pubmed.ncbi.nlm.nih.gov

Chronic tinnitus is a common symptom of the auditory system. Its pathophysiology remains incompletely understood, primarily due to its multifactorial etiology, which resembles that of other chronic conditions. As a result, effective clinical management requires interdisciplinary diagnostics and personalized therapeutic strategies. A search in PubMed using the keyword "tinnitus" covering the period from September 2023 to September 2024 yielded 1079 publications, of which the most relevant were selected and analyzed for this review summarizing current knowledge. Recent advances in tinnitus research have further refined our understanding of its pathophysiology, diagnosis, and treatment. Tinnitus is frequently triggered by cochlear damage, leading to central neuronal alterations and maladaptive plasticity. Progress in neuroimaging and psychoacoustic testing is improving diagnostic precision, while multidisciplinary treatment approaches are gaining clinical relevance and should be increasingly emphasized.

If permitted by law, could someone please share the entire article?

 

[AfroSnowman]

[Tinnitus-current developments : Overview and summary of current state of knowledge in 2024] - PubMed

Chronic tinnitus is a common symptom of the auditory system. Its pathophysiology remains incompletely understood, primarily due to its multifactorial etiology, which resembles that of other chronic conditions. As a result, effective clinical management requires interdisciplinary diagnostics and...

pubmed.ncbi.nlm.nih.gov

If permitted by law, could someone please share the entire article?

I don't speak German, but I clicked on "full text links" and it opened something that looks like a full article.

Tinnitus – aktuelle Entwicklungen

 

[Justin Mills]

Timeline for Regenerative Treatments in Cochlear Synaptopthy (tinnitus/hyperacusis)

I've attached the result of my deep research results timeline of synapse-repair drugs, cell therapies, and gene approaches are likely to be available and when, and what kind of benefit to expect.


Highlights

• 2025–26: Phase 2a synapse-repair injections (e.g., CIL001) in EU/US. Earliest path to relief is via trial enrollment (some responders may see single-digit to low double-digit % synapse reconnection → less tinnitus reactivity, better tolerance to sharp/high-pitch sounds).
• 2026–27: First-in-human auditory neuron cell therapy readouts (initially as a cochlear-implant adjunct).
• ~2029–31: If Phase 2b/3 succeed, first approvals for a synapse-repair drug; outpatient access begins.
• Early–mid 2030s: Gene therapy targeting synapse support (AAV NT-3/BDNF-like pathways) at specialized centers.
• 2030s: Improved delivery (hydrogels/microcatheters) + combination strategies → broader, more durable effects.

— See attached PDFs for details and sources.

 

[Vincent R]

Timeline for Regenerative Treatments in Cochlear Synaptopthy (tinnitus/hyperacusis)

I've attached the result of my deep research results timeline of synapse-repair drugs, cell therapies, and gene approaches are likely to be available and when, and what kind of benefit to expect.


Highlights

• 2025–26: Phase 2a synapse-repair injections (e.g., CIL001) in EU/US. Earliest path to relief is via trial enrollment (some responders may see single-digit to low double-digit % synapse reconnection → less tinnitus reactivity, better tolerance to sharp/high-pitch sounds).
• 2026–27: First-in-human auditory neuron cell therapy readouts (initially as a cochlear-implant adjunct).
• ~2029–31: If Phase 2b/3 succeed, first approvals for a synapse-repair drug; outpatient access begins.
• Early–mid 2030s: Gene therapy targeting synapse support (AAV NT-3/BDNF-like pathways) at specialized centers.
• 2030s: Improved delivery (hydrogels/microcatheters) + combination strategies → broader, more durable effects.

— See attached PDFs for details and sources.

Excellent stuff. Thanks.